This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Should You Buy Wingstop (WING) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
WINGNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Pfizer's (PFE) New Products May Drive Long-Term Sales Growth
by Kinjel Shah
Though Pfizer's (PFE) revenues from COVID products are declining sharply, the launch of some key non-COVID products in 2023 is expected to drive long-term sales and profit growth.
PFENegative Net Change NVONegative Net Change SGENPositive Net Change BNTXNegative Net Change
biotechnology
Solid Biosciences (SLDB) Stock Up as FDA Clears DMD Drug IND
by Zacks Equity Research
Solid Biosciences (SLDB) gains 28% as the FDA clears SGT-003, a gene therapy candidate, for clinical studies in the treatment of Duchenne Muscular Dystrophy.
RHHBYNegative Net Change SRPTNegative Net Change PTCTNegative Net Change SLDBNegative Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
Rocket (RCKT) Surges 40% in 3 Months on Regulatory Updates
by Zacks Equity Research
Rocket (RCKT) gains 40% in three months on positive regulatory updates on its key candidates.
DVAXNegative Net Change LGNDNegative Net Change RCKTNegative Net Change
biotechnology pharmaceuticals
Should You Buy Aspen Aerogels (ASPN) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
ASPNNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Westamerica (WABC) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
WABCNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Kodiak (KOD) Beats Q3 Earnings, Provides Pipeline Updates
by Zacks Equity Research
Kodiak (KOD) reports better-than-expected third-quarter 2023 results and provides updates regarding its pipeline development plans.
LGNDNegative Net Change APLSNegative Net Change ANIXNegative Net Change KODNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Moleculin (MBRX) Up 7% on Upbeat Updates From Annamycin Studies
by Zacks Equity Research
Moleculin (MBRX) announces positive interim data from its early-mid-stage studies of Annamycin in blood and lung cancer indications, along with encouraging third-quarter results. The stock rises 7%.
LGNDNegative Net Change MBRXPositive Net Change APLSNegative Net Change ANIXNegative Net Change
biotechnology biotechs medical pharmaceuticals
FinWise Bancorp (FINW)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
FINWNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Stock Market News for Nov 14, 2023
by Zacks Equity Research
Wall Street closed mixed on Monday as market participants awaited the release of a key inflation data.
MNDYNegative Net Change ROIVNegative Net Change FTREPositive Net Change
biotechnology internet
Immunovant (IMVT) Q2 Earnings Top Estimates, Pipeline in Focus
by Zacks Equity Research
Immunovant (IMVT) reports better-than-expected fiscal second-quarter 2023 results. Pipeline development is on track, with several data readouts scheduled from both batoclimab and IMVT-1402 programs.
LGNDNegative Net Change APLSNegative Net Change ANIXNegative Net Change IMVTNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Intellia (NTLA) Beats on Q3 Earnings, Provides Pipeline Update
by Zacks Equity Research
Intellia (NTLA) reports mixed third-quarter 2023 results. Management provides developmental and regulatory updates on its key pipeline candidates.
REGNNegative Net Change NTLAPositive Net Change APLSNegative Net Change ANIXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
2 Highly Ranked Medical Stocks to Consider After Healthy Quarterly Results
by Shaun Pruitt
After impressive quarterly results on Wednesday, here are two highly-ranked Zacks Medical sector stocks that investors may want to consider.
SRDXNegative Net Change LGNDNegative Net Change XLVNegative Net Change
biotechnology earnings investing medical
Independent Bank (IBCP) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
IBCPNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
FATE Q3 Earnings Beat on Lower Expenses, Revenues Fall Y/Y
by Zacks Equity Research
FATE reports better-than-expected third-quarter 2023 financial results, driven by lower operating expenses. The stock rises about 5% in the after-market hours.
LGNDNegative Net Change FATENegative Net Change APLSNegative Net Change ANIXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Catalyst (CPRX) Q3 Earnings Miss, Sales Top, '23 View Up
by Zacks Equity Research
Catalyst (CPRX) reports mixed third-quarter results. Firdapse and Fycompa sales continue to boost revenues. Management raises 2023 financial guidance. The stock gains 6% in the after-market hours.
LGNDNegative Net Change CPRXNegative Net Change APLSNegative Net Change ANIXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
by Ekta Bagri
Let us look at a few biotech companies, ACLX, LEGN, GRCL and EYEN, which are poised to beat third-quarter earnings estimates.
GILDNegative Net Change LEGNNegative Net Change ACLXNegative Net Change
biotechnology biotechs earnings
Bayer's (BAYRY) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Bayer (BAYRY) reports weaker-than-expected third-quarter 2023 results. Management maintains its 2023 outlook.
REGNNegative Net Change JNJNegative Net Change BAYRYNegative Net Change APLSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Pre-Markets Keep Streak Alive; RL, BIIB Beat
by Mark Vickery
The Dow rides its longest winning streak since July of this year, while the S&P and Nasdaq are enjoying their strongest moves since 2021.
BIIBNegative Net Change MGMPositive Net Change RLPositive Net Change DISNegative Net Change ARMNegative Net Change WBDNegative Net Change
apparel biotechnology biotechs consumer-discretionary earnings
GoDaddy (GDDY)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
GDDYNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
First Mid Bancshares (FMBH)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
FMBHNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Gilead (GILD) Q3 Earnings Beat, Trodelvy Fuels Oncology Sales
by Zacks Equity Research
Gilead (GILD) reports better-than-expected results for the third quarter as Trodelvy boosts oncology sales and Biktarvy maintains momentum in the HIV franchise.
GSKNegative Net Change DVAXNegative Net Change GILDNegative Net Change LGNDNegative Net Change
biotechnology biotechs earnings pharmaceuticals
bluebird (BLUE) Q3 Earnings Top; Zynteglo, Skysona Fuel Sales
by Zacks Equity Research
bluebird bio (BLUE) reports better-than-expected results in the third quarter of 2023 due to product revenues now being generated from Skysona (elivaldogene autotemcel) and Zynteglo (betibeglogene autotemcel).
DVAXNegative Net Change LGNDNegative Net Change
biotechnology biotechs earnings pharmaceuticals
Vertex (VRTX) Q3 Earnings Beat, Sales Miss, Raises '23 View
by Zacks Equity Research
Vertex's (VRTX) third-quarter results reflect a year-over-year increase in revenues. The company raises its net product sales guidance for 2023.
VRTXNegative Net Change CRSPNegative Net Change APLSNegative Net Change ANIXNegative Net Change
biotechnology biotechs crispr earnings medical pharmaceuticals
Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus
by Zacks Equity Research
Editas' (EDIT) third-quarter 2023 results reflect a year-over-year increase in revenues. The stock of the company rises 18%.
DVAXNegative Net Change ACETNegative Net Change EDITNegative Net Change APLSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals